FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118259519> ?p ?o ?g. }

• W3118259519 endingPage "S796" @default.
• W3118259519 startingPage "S795" @default.
• W3118259519 abstract "Abstract Background Advances in the survival of patients with invasive aspergillosis (IA) are jeopardized by the emergence of azole resistance in Aspergillus fumigatus, which has been associated with high probability of azole treatment failure. The clinical implications of azole-resistant IA compared to azole-susceptible IA remain unclear. Thus, we seek to describe the epidemiology and to determine the efficacy of antifungal therapy in patients with documented azole-resistant IA compared to azole-susceptible IA in patients with hematological malignancy. Methods For proven and probable IA (EORTC/MSG 2019) caused by A. fumigatus in patients with hematological malignancies retrospective data were documented, comprising demographics, diagnosis, treatment, response, and outcome. Sites provided susceptibility results or respective isolates for analysis in a central laboratory. Results Sites in 16 countries worldwide enrolled 187 cases diagnosed with IA between 2010 and 2019; 31 (16.6%) were resistant to at least one of the clinical azoles. Fungal isolates were available from 42 cases. A mixed fungal infection was reported for 32 patients (17.1%), most were related to non-fumigatus Aspergillus and non-Aspergillus molds (n=22, 69%). Most patients were male (66.8%) and overall the majority of patients were in the age groups between 50 and 89 years (71%). Amphotericin B was used for treatment in 24 (77%) patients with azole-resistant IA, compared to 76 (49%) in the azole-susceptible group (lipid-based formulation in 98%); only five (16%) patients with azole-resistant IA were treated with an azole alone vs. 57 (36%) of those with azole-susceptible IA. Overall, all-cause mortality rate was higher for patients with azole-resistant compared to azole-susceptible IA (74.2% vs. 53.8%, log rank P=0.004), the 8 patients with an azole-resistant IA treated in the intensive care unit died within 1 month (Figure 1). Details on underlying disease and survival are given in Table 1. Table 1. Underlying hematological malignancy and clinical outcome of patients with azole-resistant and azole-susceptible invasive aspergillosis Figure 1. Intensive care unit 1-year survival probability for patients with azole-resistant and azole-susceptible invasive aspergillosis Conclusion Azole-resistance in IA is associated with worse outcome, especially in critically ill patients. Susceptibility testing should be considered in patients with a suspected azole-resistant IA to support treatment decisions. Disclosures Danila Seidel, PhD, Basilea (Other Financial or Material Support, travel grant) Oliver Cornely, Prof., Actelion (Grant/Research Support)Actelion (Other Financial or Material Support, Personal fees)Al Jazeera Pharmaceuticals (Consultant)Allecra Therapeutics (Other Financial or Material Support, Personal fees)Amplyx (Other Financial or Material Support, Personal fees)Amplyx (Grant/Research Support)Astellas (Grant/Research Support)Astellas (Other Financial or Material Support, Personal fees)Basilea (Other Financial or Material Support, Personal fees)Basilea (Grant/Research Support)Biosys UK Limited (Other Financial or Material Support, Personal fees)Cidara (Other Financial or Material Support, Personal fees)Cidara (Grant/Research Support)Da Volterra (Grant/Research Support)Da Volterra (Other Financial or Material Support, Personal fees)Entasis (Other Financial or Material Support, Personal fees)F2G (Other Financial or Material Support)F2G (Grant/Research Support)Gilead (Grant/Research Support)Gilead (Other Financial or Material Support, Personal fees)Grupo Biotoscana (Other Financial or Material Support, Personal fees)Janssen Pharmaceuticals (Grant/Research Support)Matinas (Other Financial or Material Support, Personal fees)Medicines Company (Grant/Research Support)MedPace (Grant/Research Support)MedPace (Other Financial or Material Support, Personal fees)Melinta Therapeutics (Grant/Research Support)Menarini Ricerche (Other Financial or Material Support, Personal fees)Merck/MSD (Other Financial or Material Support, Personal fees)Merck/MSD (Grant/Research Support)Mylan Pharmaceuticals (Consultant)Nabriva Therapeutics (Other Financial or Material Support, Personal fees)Octapharma (Other Financial or Material Support, Personal fees)Paratek Pharmaceuticals (Other Financial or Material Support, Personal fees)Pfizer (Other Financial or Material Support, Personal fees)Pfizer (Grant/Research Support)PSI (Other Financial or Material Support, Personal fees)Rempex (Other Financial or Material Support, Personal fees)Roche Diagnostics (Other Financial or Material Support, Personal fees)Scynexis (Other Financial or Material Support, Personal fees)Scynexis (Grant/Research Support)Seres Therapeutics (Other Financial or Material Support, Personal fees)Tetraphase (Other Financial or Material Support, Personal fees) Philipp Koehler, MD, Akademie für Infektionsmedizin e.V., (Other Financial or Material Support, Personal fees)Astellas Pharma GmbH (Other Financial or Material Support, Personal fees)Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany (Other Financial or Material Support, Other)Gilead Sciences GmbH (Other Financial or Material Support, Personal fees)GPR Academy Ruesselsheim (Speaker’s Bureau)Miltenyi Biotec GmbH (Other Financial or Material Support, Non-financial support)MSD Sharp & Dohme GmbH (Other Financial or Material Support, Personal fees)Noxxon N.V. (Speaker’s Bureau)University Hospital, LMU Munich (Other Financial or Material Support, Personal fees) Katrien Lagrou, n/a, FUJIFILM WAKO (Speaker’s Bureau)Gilead (Consultant, Speaker’s Bureau)MSD (Consultant, Speaker’s Bureau, Other Financial or Material Support, travel grant)Pfizer (Speaker’s Bureau, travel grant)SMB Laboratoires Brussels (Consultant) Zdenek Racil, n/a, Astellas (Grant/Research Support, Speaker’s Bureau, travel grant) Blandine Rammaert, n/a, Gilead (Speaker’s Bureau, Other Financial or Material Support, travel grant)Merck/MSD (Speaker’s Bureau)Pfizer (Other Financial or Material Support, travel grant) Nikolay Klimko, n/a, Astellas (Speaker’s Bureau)Gilead (Speaker’s Bureau)Merck/MSD (Speaker’s Bureau)Pfizer (Speaker’s Bureau) Sung-Yeon Cho, MD, Gilead (Grant/Research Support, Speaker’s Bureau)Merck Sharp & Dohme (Grant/Research Support, Speaker’s Bureau)Pfizer (Grant/Research Support, Speaker’s Bureau)" @default.
• W3118259519 created "2021-01-18" @default.
• W3118259519 creator A5009844840 @default.
• W3118259519 creator A5012104719 @default.
• W3118259519 creator A5012922109 @default.
• W3118259519 creator A5018433469 @default.
• W3118259519 creator A5019885844 @default.
• W3118259519 creator A5022459124 @default.
• W3118259519 creator A5022800391 @default.
• W3118259519 creator A5024606224 @default.
• W3118259519 creator A5026731919 @default.
• W3118259519 creator A5027423676 @default.
• W3118259519 creator A5035290084 @default.
• W3118259519 creator A5036912140 @default.
• W3118259519 creator A5036932689 @default.
• W3118259519 creator A5039877689 @default.
• W3118259519 creator A5041259114 @default.
• W3118259519 creator A5045221135 @default.
• W3118259519 creator A5046364973 @default.
• W3118259519 creator A5050159426 @default.
• W3118259519 creator A5054798761 @default.
• W3118259519 creator A5055053269 @default.
• W3118259519 creator A5056215610 @default.
• W3118259519 creator A5057319606 @default.
• W3118259519 creator A5057866828 @default.
• W3118259519 creator A5058496677 @default.
• W3118259519 creator A5060155106 @default.
• W3118259519 creator A5062137164 @default.
• W3118259519 creator A5062937497 @default.
• W3118259519 creator A5064996258 @default.
• W3118259519 creator A5065416055 @default.
• W3118259519 creator A5067383538 @default.
• W3118259519 creator A5067405381 @default.
• W3118259519 creator A5071487615 @default.
• W3118259519 creator A5074930464 @default.
• W3118259519 creator A5078813273 @default.
• W3118259519 creator A5079451879 @default.
• W3118259519 creator A5081446167 @default.
• W3118259519 creator A5086668079 @default.
• W3118259519 date "2020-10-01" @default.
• W3118259519 modified "2023-10-06" @default.
• W3118259519 title "1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study" @default.
• W3118259519 doi "https://doi.org/10.1093/ofid/ofaa439.1778" @default.
• W3118259519 hasPublicationYear "2020" @default.
• W3118259519 type Work @default.
• W3118259519 sameAs 3118259519 @default.
• W3118259519 citedByCount "0" @default.
• W3118259519 crossrefType "journal-article" @default.
• W3118259519 hasAuthorship W3118259519A5009844840 @default.
• W3118259519 hasAuthorship W3118259519A5012104719 @default.
• W3118259519 hasAuthorship W3118259519A5012922109 @default.
• W3118259519 hasAuthorship W3118259519A5018433469 @default.
• W3118259519 hasAuthorship W3118259519A5019885844 @default.
• W3118259519 hasAuthorship W3118259519A5022459124 @default.
• W3118259519 hasAuthorship W3118259519A5022800391 @default.
• W3118259519 hasAuthorship W3118259519A5024606224 @default.
• W3118259519 hasAuthorship W3118259519A5026731919 @default.
• W3118259519 hasAuthorship W3118259519A5027423676 @default.
• W3118259519 hasAuthorship W3118259519A5035290084 @default.
• W3118259519 hasAuthorship W3118259519A5036912140 @default.
• W3118259519 hasAuthorship W3118259519A5036932689 @default.
• W3118259519 hasAuthorship W3118259519A5039877689 @default.
• W3118259519 hasAuthorship W3118259519A5041259114 @default.
• W3118259519 hasAuthorship W3118259519A5045221135 @default.
• W3118259519 hasAuthorship W3118259519A5046364973 @default.
• W3118259519 hasAuthorship W3118259519A5050159426 @default.
• W3118259519 hasAuthorship W3118259519A5054798761 @default.
• W3118259519 hasAuthorship W3118259519A5055053269 @default.
• W3118259519 hasAuthorship W3118259519A5056215610 @default.
• W3118259519 hasAuthorship W3118259519A5057319606 @default.
• W3118259519 hasAuthorship W3118259519A5057866828 @default.
• W3118259519 hasAuthorship W3118259519A5058496677 @default.
• W3118259519 hasAuthorship W3118259519A5060155106 @default.
• W3118259519 hasAuthorship W3118259519A5062137164 @default.
• W3118259519 hasAuthorship W3118259519A5062937497 @default.
• W3118259519 hasAuthorship W3118259519A5064996258 @default.
• W3118259519 hasAuthorship W3118259519A5065416055 @default.
• W3118259519 hasAuthorship W3118259519A5067383538 @default.
• W3118259519 hasAuthorship W3118259519A5067405381 @default.
• W3118259519 hasAuthorship W3118259519A5071487615 @default.
• W3118259519 hasAuthorship W3118259519A5074930464 @default.
• W3118259519 hasAuthorship W3118259519A5078813273 @default.
• W3118259519 hasAuthorship W3118259519A5079451879 @default.
• W3118259519 hasAuthorship W3118259519A5081446167 @default.
• W3118259519 hasAuthorship W3118259519A5086668079 @default.
• W3118259519 hasBestOaLocation W31182595191 @default.
• W3118259519 hasConcept C126322002 @default.
• W3118259519 hasConcept C16005928 @default.
• W3118259519 hasConcept C203014093 @default.
• W3118259519 hasConcept C2776391196 @default.
• W3118259519 hasConcept C2778566413 @default.
• W3118259519 hasConcept C2779320740 @default.
• W3118259519 hasConcept C2779548794 @default.
• W3118259519 hasConcept C2779629538 @default.
• W3118259519 hasConcept C2779787849 @default.
• W3118259519 hasConcept C2780315139 @default.
• W3118259519 hasConcept C2780651595 @default.
• W3118259519 hasConcept C2780690907 @default.

• next